Cross-Sector entity
Solius Labs is the most frequent co-covered peer, appearing in 3 of the 12 tracked stories. The 150-day window averages about 0.6 stories each week. The busiest single day carried 3. regulation accounts for 5 of the 12 tracked stories, while 5 other categories carry the remainder.
12 verified stories tracked
Last mentioned: Jun 18, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Solius Labs is the most frequent co-covered peer, appearing in 3 of the 12 tracked stories. The 150-day window averages about 0.6 stories each week. The busiest single day carried 3. regulation accounts for 5 of the 12 tracked stories, while 5 other categories carry the remainder. Each carries 3.5 original sources on average. This profile follows 12 Cross-Sector stories mentioning U.S. Food and Drug Administration (FDA) across the period from February 19, 2026 to July 18, 2026. Negative sentiment appears in 8% of the tracked stories.
Computed from the 12 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering U.S. Food and Drug Administration (FDA). Shared-story counts are live from our verified record — not editorial picks.
FDA links outbreak to Taco Bell lettuce
FDA announces traceback results identifying shredded iceberg lettuce from Mexico as the source; Taylor Farms announces voluntary removal of all central Mexican iceberg lettuce from U.S. market.
Last illness onset
Final reported onset date within the outbreak window.
Comment Period Close
Expected deadline for industry stakeholders to submit feedback on the proposed framework.
First illness onset
First reported case of cyclospora infection linked to the outbreak.
Customized Drug Proposal
FDA formally proposes the new system for approving bespoke therapies for rare diseases.
Quicker Path Formalized
Official rollout of the streamlined regulatory framework for gene therapy approvals.
CBER Staffing Surge
FDA completes hiring of 100+ new reviewers dedicated to biologics and gene therapy.
SCOTUS Ruling
Supreme Court preserves access to mifepristone by ruling plaintiffs lacked standing in FDA challenge.
SCOTUS Mifepristone Hearing
Supreme Court hears arguments regarding the FDA's regulation of medication abortion pills.
National Data Release
Reports confirm U.S. abortion numbers held steady despite 14 state-level bans.
START Pilot Program
FDA launches the Support for clinical Trials Advancing Rare disease Therapeutics pilot.
Shield Law Expansion
States like MA and NY implement laws protecting providers from out-of-state legal actions.
FDORA Enacted
The Food and Drug Omnibus Reform Act authorizes the FDA to establish a Platform Technology Designation.
Dobbs Decision
U.S. Supreme Court overturns Roe v. Wade, returning abortion regulation to the states.
Dobbs Decision
SCOTUS overturns Roe v. Wade, triggering state-level bans and increasing demand for pills.
Telehealth Shift
FDA permanently removes the requirement that mifepristone be dispensed in person.
First Gene Therapy Approved
FDA approves Luxturna for a rare form of inherited vision loss.
Label Update
FDA expands usage to 70 days gestation and reduces required office visits.
FDA Approval
FDA approves Mifeprex (mifepristone) for medical termination of pregnancy.
Orphan Drug Act
Congress passes legislation providing financial incentives for rare disease research.
Taco Bell’s lettuce supplier halts all Mexican imports after FDA traceback links 1,644 cyclospora cases to a single farm. The recall spotlights fresh-produce supply chain vulnerabilities and traceability gaps.
Source: Taylor Farms (us) · Taylor Farms (us)
The FDA’s accelerated approval of TRUTAKNA marks the first BAFF/APRIL inhibitor for IgA nephropathy, showing a 42% UPCR reduction over placebo. Healthcare providers now have a therapy targeting upstream disease drivers, with launch imminent and a confirmatory trial ongoing.
Vera Therapeutics scores an accelerated approval for TRUTAKNA in IgA nephropathy, touting a 42% UPCR reduction vs placebo in Phase 3 ORIGIN 3. The dual BAFF/APRIL inhibitor enters a competitive market with a surrogate endpoint—investors await the confirmatory eGFR data.
Source: dailypolitical.com · tickerreport.com
Bainbridge Island-based startup Solius Labs announces the launch of its FDA-cleared personalized sunlight device, Solius Pro, targeting the growing consumer health and wellness market. The move positions the company at the forefront of a new category of over-the-counter light therapy without prescription.
Solius Labs launches the first OTC FDA-cleared personalized UVB light therapy device, claiming significant health benefits with minimal UV risk. For health consumers, it could offer a convenient way to boost vitamin D and improve mood without sun exposure.
The FDA has established a novel product code for Solius Pro, an over-the-counter UVB light therapy device that claims to deliver biological benefits of sunlight with dramatically reduced risk. The move signals regulatory recognition of personalized home phototherapy as a distinct category.
Source: Business Wire (ca) · Business Wire (ca)
Medication abortion has surged to account for the majority of pregnancy terminations in the U.S., driven by telehealth expansion and mail-order access. This shift has catalyzed a sophisticated legal and legislative counter-offensive aimed at the FDA's regulatory authority and the distribution of pharmaceutical products.
Despite the implementation of near-total bans in 14 states, the national volume of abortions in the U.S. has remained steady or increased. This resilience is driven by a surge in medication abortion, the expansion of telehealth, and the emergence of state 'shield laws' that protect providers across jurisdictional lines.
Source: kansaspublicradio.org · ypradio.org
The U.S. Food and Drug Administration is introducing a new incentive program that provides financial bonuses to staff members who complete drug application reviews ahead of schedule. This move aims to streamline the regulatory pipeline and reduce the backlog of pending therapies, though it raises questions regarding the balance between speed and clinical rigor.
The FDA has proposed a landmark regulatory system designed to accelerate the approval of customized, 'bespoke' medicines for ultra-rare diseases. The framework allows manufacturers to leverage data from established platform technologies to streamline the development of individualized genomic treatments.
Source: journalgazette.net · wyff4.com
The FDA has launched a streamlined regulatory pathway designed to expedite the development and review of gene therapies, particularly for rare diseases. This initiative marks a significant shift toward using surrogate endpoints and flexible trial designs to bring life-saving treatments to market faster.
NG Biotech and Hardy Diagnostics have received FDA Breakthrough Device Designation for two rapid diagnostic assays targeting multidrug-resistant pathogens. The NG-TEST Candida auris and NG-TEST Aci assays provide rapid, point-of-care identification of high-priority healthcare-associated infections.
Source: Yahoo · medicaldevice-network.com
